Karmanos Cancer Institute Raises Awareness for Sarcoma This July

In a significant initiative, the Barbara Ann Karmanos Cancer Institute is joining forces with cancer centers and organizations nationwide to recognize July as Sarcoma Awareness Month. This annual observance aims to shed light on sarcomas, which are rare cancers that account for about 1% of all adult cancer cases and approximately 15% of cancers diagnosed in children. In 2025, it is estimated that over 13,500 new sarcoma cases will be identified across the United States.

Understanding Sarcoma

Sarcomas are unique malignancies that originate in the body’s connective tissues, which include bones, muscle, and fat, among others. Dr. Steve Kim, a surgical oncologist at Karmanos, elaborates that sarcomas can be categorized into soft tissue sarcomas, more prevalent among adults, and bone sarcomas, which are generally more common in children.

Risk Factors Associated with Sarcoma

Although certain hereditary cancer syndromes can increase the likelihood of developing soft tissue sarcomas, lifestyle factors such as diet, exercise, and smoking do not show a direct correlation with increased risks for this type of cancer. This notable distinction underscores the importance of awareness and understanding when it comes to prevention and early detection.

Treatment Options at Karmanos

Sarcomas often manifest as slowly growing masses, primarily in the limbs. Given their rarity and sometimes aggressive nature, it is crucial for patients to seek treatment at advanced medical facilities like the Karmanos Cancer Institute, which specializes in these complex tumors. The institute is home to the Sarcoma Oncology Multidisciplinary Team (MDT), consisting of a dedicated group of oncologists, radiologists, pathologists, and other healthcare professionals who focus exclusively on sarcoma treatment.

This collaborative team approach ensures that each patient receives a tailored treatment plan that leverages the collective expertise of specialists in various fields. Their commitment to advancing sarcoma treatment includes conducting clinical trials and engaging in translational research aimed at improving patient outcomes.

Why Choose Karmanos?

Karmanos Cancer Institute is renowned for its transformative cancer care, education, and research. As part of the McLaren Health Care network, it stands as the most extensive provider of cancer services in Michigan. With its main facility located in downtown Detroit, Karmanos has pioneered advancements in cancer treatment for over 75 years.

Notably, Karmanos holds a comprehensive cancer center designation from the National Cancer Institute, underscoring its commitment to providing high-quality care. Moreover, its academic partnership with the Wayne State University School of Medicine allows further dedication to cancer research and education, striving for the development of new treatment standards while enhancing survivorship.

For those seeking specialized care, Karmanos invites patients to schedule an appointment with its Sarcoma Oncology MDT. With resources tailored specifically for sarcoma treatment, patients are assured they will receive some of the best care available in the nation.

Connect with Karmanos Cancer Institute

For further information about sarcoma and how Karmanos Cancer Institute is working to fight this rare type of cancer, you can reach out at 1-800-KARMANOS (800-527-6266) or visit karmanos.org. Stay connected with Karmanos on social media through Facebook, Twitter, LinkedIn, and YouTube to follow their impactful work and ongoing contributions to cancer awareness and research.